微流控
商业化
药物发现
纳米技术
微流控芯片
计算机科学
吞吐量
生化工程
芯片上器官
风险分析(工程)
生物信息学
材料科学
医学
工程类
生物
业务
营销
电信
无线
作者
Chun‐Wei Chi,Ah Rezwanuddin Ahmed,Zeynep Dereli‐Korkut,Sihong Wang
出处
期刊:Bioanalysis
[Newlands Press Ltd]
日期:2016-05-01
卷期号:8 (9): 921-937
被引量:58
标识
DOI:10.4155/bio-2016-0028
摘要
The current state of screening methods for drug discovery is still riddled with several inefficiencies. Although some widely used high-throughput screening platforms may enhance the drug screening process, their cost and oversimplification of cell–drug interactions pose a translational difficulty. Microfluidic cell-chips resolve many issues found in conventional HTS technology, providing benefits such as reduced sample quantity and integration of 3D cell culture physically more representative of the physiological/pathological microenvironment. In this review, we introduce the advantages of microfluidic devices in drug screening, and outline the critical factors which influence device design, highlighting recent innovations and advances in the field including a summary of commercialization efforts on microfluidic cell chips. Future perspectives of microfluidic cell devices are also provided based on considerations of present technological limitations and translational barriers.
科研通智能强力驱动
Strongly Powered by AbleSci AI